Krause Kevin Michael 4/A
4/A · AN2 Therapeutics, Inc. · Filed Mar 29, 2024
Insider Transaction Report
Form 4/AAmended
Krause Kevin Michael
Chief Strategy Officer
Transactions
- Award
Common Stock
2024-03-15+30,000→ 31,914 total
Footnotes (1)
- [F1]Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.